Spyre Therapeutics
SYRE · NASDAQ
$91.40+$6.68 (+7.88%)TodayMarket closed ·
Prev close $84.72
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 39.1% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$0.82
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.7738 | -$0.36 | +53.5% |
| Q1 FY26 | -$0.6794 | -$0.74 | −8.9% |
| Q4 FY25 | -$0.7903 | -$0.70 | +11.4% |
| Q3 FY25 | -$0.7613 | -$0.15 | +80.3% |
| Q2 FY25 | -$0.7687 | -$0.77 | −0.2% |
| Q1 FY25 | -$0.8578 | -$0.60 | +30.1% |
| Q4 FY24 | -$1.01 | -$0.81 | +20.1% |
| Q3 FY24 | -$0.8409 | -$1.36 | −61.7% |
Earnings calls
- Citigroup’s Biopharma Back to School Summit 2026
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Special Call - Spyre Therapeutics, Inc.
- Leerink Global Healthcare Conference 2026
- TD Cowen 46th Annual Health Care Conference
- Special Call - Spyre Therapeutics, Inc.
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- Jefferies Global Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.